Pyruvate Kinase Deficiency Clinical Trial
Official title:
An Open-Label, Multicenter, Extension Study of AG-348 in Adult Subjects With Pyruvate Kinase Deficiency Previously Enrolled in AG-348 Studies
Verified date | June 2024 |
Source | Agios Pharmaceuticals, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a multicenter, open-label, extension study to evaluate the long-term safety, tolerability, and efficacy of treatment with AG-348 in participants who were previously enrolled in Study AG348-C-006 or Study AG348-C-007.
Status | Active, not recruiting |
Enrollment | 90 |
Est. completion date | June 2024 |
Est. primary completion date | June 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Be willing and able to comply with study visits and procedures; - Have signed written informed consent prior to participating in this extension study; - Have completed either antecedent study AG348-C-006 or AG348-C-007 through the Part 2 Week 24 Visit; - Cohorts 2 and 3: Have demonstrated clinical benefit from AG-348 treatment in the antecedent study, in the opinion of the Investigator; - For women of reproductive potential, have a negative pregnancy test during screening; - For women of reproductive potential as well as men with partners who are women of reproductive potential, be abstinent as part of their usual lifestyle, or agree to use 2 forms of contraception, 1 of which must be considered highly effective, from the time of giving informed consent, during the study, and for 28 days following the last dose of study drug for women and 90 days following the last dose of study drug for men. Exclusion Criteria: - Have a significant medical condition (including clinically significant laboratory abnormality) that developed during his/her antecedent AG- 348 study that confers an unacceptable risk to participating in this extension study, that could confound the interpretation of the study data, and/or that compromises the ability of the participant to complete study visits and procedures. - Are currently pregnant or breastfeeding. - Have a splenectomy scheduled during the study treatment period. - Meet the withdrawal criteria of his/her antecedent AG-348 study during screening of this extension study. - Are currently receiving medications that are strong inhibitors of cytochrome P450 (CYP)3A4 that have not been stopped for a duration of at least 5 days or a time frame equivalent to 5 half-lives (whichever is longer) before start of study drug; or strong inducers of CYP3A4 that have not been stopped for a duration of at least 28 days or a time frame equivalent to 5 half-lives (whichever is longer) before start of study drug on this extension study. - Have received anabolic steroids, including testosterone preparations, within 28 days prior to start of study drug on this extension study. - Have received hematopoietic stimulating agents (eg, erythropoietins, granulocyte colony stimulating factors, thrombopoietins) within 28 days prior to start of study drug on this extension study. - Have exposure to any investigational drug other than AG-348, device, or procedure within 3 months prior to start of study drug on this extension study. |
Country | Name | City | State |
---|---|---|---|
Brazil | UNICAMP - Hemocentro | São Paulo | |
Canada | McMaster University | Hamilton | Ontario |
Denmark | Herlev University Hospital | Herlev | |
France | CHU Hopitaux de Bordeaux - Hôpital Saint-André | Bordeaux | |
France | CHU Hôpital Henri Mondor | Créteil | |
France | Hospital La Timone | Marseille | |
France | Institut Universitaire du Cancer de Toulouse - Oncopole | Toulouse | |
Germany | Charite - UB - CVK - Medizinische Klinik | Berlin | |
Germany | Universitätsklinik Würzburg | Würzburg | |
Ireland | St James's Hospital | Dublin 8 | |
Italy | Ospedale Galliera | Genova | |
Italy | Osp Maggiore Policlinico Milano | Milano | |
Italy | AORN Cardarelli | Napoli | |
Italy | Università della Campania "Luigi Vanvitelli" | Napoli | |
Japan | Kyoto Katsura Hospital | Kyoto | |
Japan | Kansai Medical University, Dep. of Pediatrics, Hirakata Hospital | Osaka | |
Japan | Tohoku University Hospital | Sendai | Miyagi |
Japan | Toho University Omori Medical Center | Tokyo | |
Japan | Mie University Hospital | Tsu-shi | Mie |
Korea, Republic of | Yeungnam University Hospital | Daegu | |
Netherlands | Van Creveldkliniek | Utrecht | |
Spain | Hospital. U. Vall d'Hebron | Barcelona | |
Spain | Hospital Universitario La Paz | Madrid | |
Spain | Htal Clínico Universitario Virgen de la Arrixaca. | Murcia | |
Switzerland | Centre Hospitalier Universitaire Vaudois (CHUV) | Vaud (Lausanne) | |
Thailand | Faculty of Medicine Siriraj Hospital | Bangkok | |
Turkey | Hacettepe University Faculty of Medicine | Ankara | |
United Kingdom | Addenbrooke's Hospital | Cambridge | |
United Kingdom | Imperial College Healthcare NHS Trust | London | |
United Kingdom | University College London | London | |
United States | Boston Children's Hospital | Boston | Massachusetts |
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio |
United States | Wayne State University School of Medicine | Detroit | Michigan |
United States | Duke University Medical Center | Durham | North Carolina |
United States | Houston Methodist Research Institute | Houston | Texas |
United States | Indiana Hemophilia & Thrombosis Center Inc. | Indianapolis | Indiana |
United States | UCSF Benioff Children's Hospital, Oakland | Oakland | California |
United States | Phoenix Children's Hospital | Phoenix | Arizona |
United States | University of Utah | Salt Lake City | Utah |
United States | Seattle Cancer Care Alliance | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Agios Pharmaceuticals, Inc. |
United States, Brazil, Canada, Denmark, France, Germany, Ireland, Italy, Japan, Korea, Republic of, Netherlands, Spain, Switzerland, Thailand, Turkey, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | From baseline to safety follow-up (up to 198 weeks) | ||
Primary | Number of Participants with AEs Leading to Dose Reduction, Treatment Interruption and Treatment Discontinuation | From baseline to safety follow-up (up to 198 weeks) | ||
Secondary | Percentage of Participants Achieving a Hemoglobin (Hb) Response in Participants Who Previously Received Placebo in Study AG348-C-006 | Weeks 16, 20, 24 | ||
Secondary | Area Under the Concentration-Time Curve (AUC) of AG-348 in Participants Who Previously Received Placebo in Study AG348-C-006 | Week 12: pre-dose, post-dose at 30 minutes, 1 hour (h), 2 h, 4 h, 8 h | ||
Secondary | Maximum Observed Concentration of AG-348 in Participants Who Previously Received Placebo in Study AG348-C-006 | Week 12: pre-dose, post-dose at 30 minutes, 1 h, 2 h, 4 h, 8 h | ||
Secondary | Change from Baseline in Hb Concentration | From baseline up to Week 193 (Day 1) | ||
Secondary | Change from Baseline in Bilirubin | From baseline up to Week 193 (Day 1) | ||
Secondary | Change from Baseline in Lactate Dehydrogenase (LDH) | From baseline up to Week 193 (Day 1) | ||
Secondary | Change from Baseline in Haptoglobin Levels | From baseline up to Week 193 (Day 1) | ||
Secondary | Change from Baseline in Reticulocyte Percentages | From baseline up to Week 193 (Day 1) | ||
Secondary | Change from Baseline in Number of Transfusion Events | From baseline up to Week 193 (Day 1) | ||
Secondary | Change from Baseline in Number of Red Blood Cell (RBC) Units Transfused | From baseline up to Week 193 (Day 1) | ||
Secondary | Change from Baseline in Health-Related Quality of Life (HRQoL) Patient-Reported Outcome (PRO) Scores: Pyruvate Kinase Deficiency Diary (PKDD) | From baseline up to Week 193 (Day 1) | ||
Secondary | Change from Baseline in HRQoL PRO Scores: Pyruvate Kinase Deficiency Impact Assessment (PKDIA) | From baseline up to Week 193 (Day 1) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03559699 -
A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)
|
Phase 3 | |
Active, not recruiting |
NCT02476916 -
A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency
|
Phase 2 | |
Active, not recruiting |
NCT04105166 -
Gene Therapy for Pyruvate Kinase Deficiency (PKD)
|
Phase 1 | |
Enrolling by invitation |
NCT05777993 -
A Study to Provide Continued Access to Mitapivat for Participants Who Previously Completed an Agios-Sponsored Mitapivat Study
|
Phase 4 | |
Completed |
NCT04995315 -
Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG348-C-008
|
||
Terminated |
NCT04964323 -
Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO)
|
||
Completed |
NCT03866590 -
Pyruvate Kinase Deficiency Epidemiological Study (PIECE)
|
||
Recruiting |
NCT04902833 -
Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms
|
||
Completed |
NCT02053480 -
Pyruvate Kinase Deficiency Natural History Study
|
||
Completed |
NCT03548220 -
A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)
|
Phase 3 | |
Not yet recruiting |
NCT06422351 -
Clinical Trial to Evaluate the Efficacy of Gene Therapy for Pyruvate Kinase Deficiency
|
Phase 2 | |
Recruiting |
NCT03481738 -
Pyruvate Kinase Deficiency Global Longitudinal Registry
|